Results 1 to 10 of about 29,458 (191)

Therapeutic drug monitoring of daptomycin in a critically ill patient cohort [PDF]

Frontiers in Medicine
BackgroundPharmacokinetics of antimicrobial agents are altered in critically ill patients. Therefore, therapeutic drug monitoring (TDM) has gained much attention in recent years.
Rubi Stephani Hellwege, Mattia Müller, Rolf Erlebach, Onur Sazpinar, Alix Buhlmann, Reto A. Schuepbach, Sascha David, Sascha David, Daniel A. Hofmaenner   +8 more
doaj   +2 more sources

In vitro persistence of clinical methicillin-resistant Staphylococcus aureus isolates from bone and joint infections after exposure to daptomycin, telavancin, and vancomycin [PDF]

Microbiology Spectrum
Bacterial persistence is linked to chronic infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Understanding the persister profiles of daptomycin, telavancin, and vancomycin is crucial because MRSA bone and joint infections (BJIs ...
Aliaa Fouad, Joseph L. Kuti, Christian M. Gill   +2 more
doaj   +2 more sources

Daptomycin [PDF]

Journal of Antimicrobial Chemotherapy, 2017
Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of Gram-positive infections including complicated skin and skin structure infections, right-sided infective endocarditis, bacteraemia, meningitis, sepsis and urinary tract infections.
Mohsen, Heidary, Azar Dohkt, Khosravi, Saeed, Khoshnood, Mohammad Javad, Nasiri, Saleh, Soleimani, Mehdi, Goudarzi   +5 more
  +5 more sources

The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics. [PDF]

, 2013
Life expectancy for people diagnosed with HIV has improved dramatically however the number of new infections in the UK remains high. Understanding patterns of sexual behaviour among people living with diagnosed HIV, and the factors associated with having
Alec Miners, Alison Rodger, Andrew N. Phillips, Andrew Speakman, Anna-Maria Geretti, Anne M. Johnson, Beatriz G. J. Grinsztejn, Ed Wilkins, , Fiona C. Lampe, Graham Hart, Jane Anderson, Jeffrey McDonnell, Jonathan Elford, Kazeem Aderogba, Lorraine Sherr, Margaret Johnson, Martin Fisher, Monica Lascar, Nicky Perry, Rebecca O’Connell, Richard Gilson, Simon Collins, Simon Edwards, William J. Burman   +23 more
core   +19 more sources

Acquisition of Daptomycin Resistance by Enterococcus faecium Confers Collateral Sensitivity to Glycopeptides

Frontiers in Microbiology, 2022
Daptomycin is a last-line antibiotic used in the treatment of multidrug-resistant Enterococcus faecium infections. Alarmingly, daptomycin-resistant E. faecium isolates have emerged.
Weiliang Zeng, Luozhu Feng, Changrui Qian, Tao Chen, Sipei Wang, Ying Zhang, Xiangkuo Zheng, Lingbo Wang, Shixing Liu, Tieli Zhou, Yao Sun   +10 more
doaj   +1 more source

A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category

Infectious Diseases and Therapy, 2023
Introduction Daptomycin doses 8–12 mg/kg are recommended for susceptible dose-dependent Enterococcus species. However, data remain limited on safety outcomes of such dosing, compared to standard 4–6 mg/kg dosing.
Ming M. Zhang, Ryan W. Stevens, Jennifer L. Adema, Kristin C. Mara, Audrey N. Schuetz, Aaron J. Tande, Christina G. Rivera   +6 more
doaj   +1 more source

Daptomycin Resistance Occurs Predominantly in vanA-Type Vancomycin-Resistant Enterococcus faecium in Australasia and Is Associated With Heterogeneous and Novel Mutations

Frontiers in Microbiology, 2021
Healthcare associated infections caused by vancomycin-resistant Enterococcus faecium (VREfm) have a major impact on health outcomes. VREfm is difficult to treat because of intrinsic and acquired resistance to many clinically used antimicrobials, with ...
Lucy Li, Charlie Higgs, Adrianna M. Turner, Yi Nong, Claire L. Gorrie, Claire L. Gorrie, Norelle L. Sherry, Norelle L. Sherry, Norelle L. Sherry, Kristin H. Dyet, Torsten Seemann, Deborah A. Williamson, Deborah A. Williamson, Timothy P. Stinear, Benjamin P. Howden, Benjamin P. Howden, Benjamin P. Howden, Glen P. Carter, Glen P. Carter   +18 more
doaj   +1 more source

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. [PDF]

PLoS ONE, 2016
Our objective was to study the pharmacodynamics of daptomycin in the presence of varying concentrations of human serum (HS) in vitro to quantify the fraction of daptomycin that is 'active'.
Samira M Garonzik, Justin R Lenhard, Alan Forrest, Patricia N Holden, Jϋrgen B Bulitta, Brian T Tsuji   +5 more
doaj   +1 more source

Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis

BMC Microbiology, 2020
Background Viridans group streptococci of the Streptococcus mitis-oralis subgroup are important endovascular pathogens. They can rapidly develop high-level and durable non-susceptibility to daptomycin both in vitro and in vivo upon exposure to daptomycin.
Allison Parrett, Joseph M. Reed, Stewart G. Gardner, Nagendra N. Mishra, Arnold S. Bayer, Robert Powers, Greg A. Somerville   +6 more
doaj   +1 more source

Removal of peptidoglycan and inhibition of active cellular processes leads to daptomycin tolerance in Enterococcus faecalis.

PLoS ONE, 2021
Daptomycin is a cyclic lipopeptide antibiotic used in the clinic for treatment of severe enterococcal infections. Recent reports indicate that daptomycin targets active cellular processes, specifically, peptidoglycan biosynthesis. Within, we examined the
Rachel D Johnston, Brittni M Woodall, Johnathan Harrison, Shawn R Campagna, Elizabeth M Fozo   +4 more
doaj   +1 more source